PolyPid Ltd. (NASDAQ:PYPD – Get Rating) was up 4.8% during trading on Wednesday . The company traded as high as $0.39 and last traded at $0.37. Approximately 94,833 shares traded hands during mid-day trading, a decline of 67% from the average daily volume of 288,958 shares. The stock had previously closed at $0.35.
PolyPid Stock Down 7.0 %
The business has a fifty day moving average of $0.42 and a 200 day moving average of $0.64. The firm has a market cap of $6.84 million, a P/E ratio of -0.22 and a beta of 1.25. The company has a quick ratio of 2.75, a current ratio of 2.75 and a debt-to-equity ratio of 0.59.
PolyPid (NASDAQ:PYPD – Get Rating) last announced its quarterly earnings results on Wednesday, May 10th. The company reported ($0.28) earnings per share (EPS) for the quarter. On average, equities research analysts predict that PolyPid Ltd. will post -1.05 EPS for the current year.
Institutional Investors Weigh In On PolyPid
PolyPid Company Profile
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs.
- Get a free copy of the StockNews.com research report on PolyPid (PYPD)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.